Treatment of Type 2 diabetes mellitus (T2DM): Can GLP-1 Receptor Agonists fill in the gaps?
A review on possible use Glucagon-like peptide-1 receptor drugs for Type 2 diabetes mellitus (T2DM) treatment
Keywords:Diabetes, treatment, Incretin, harmones, Diabetes drugs, Medicinal Chemistry
Type 2 diabetes mellitus (T2DM) is a chronic metabolic syndrome, which occurs due to increased glucose levels in the human body. There has been lot of work in developing novel approaches to tackle this disease. GLP-1 receptor (GLP-1R), one of the class-B G-protein-coupled receptors (GPCR), is a budding molecular target to design drugs for treating type 2 diabetes. In this review, authors have summarized the physiological actions of Glucagon-like peptide-1 receptor (GLP-1R) and current available drugs based on GLP-1 RAs. Some of the exemplary studies in this area have been examined in detail. Authors conclude that development of degradation-resistant, long-acting GLP-1 receptor agonists is a promising area of research and lot of work needs to be done to understand its mechanism of action.
How to Cite
Rights and Permission
The copyright holder for contents - ScienceIn
Permission: The readers can re-use the graphics and images for educational and academic purpose (for reproduction in Review etc) provided that source reference is cited properly.